Immodulon announces Notice of Allowance for two U.S. Patent Applications related to IMM-101 in combination with Immune Checkpoint Inhibitors

Claims cover methods of treating pancreatic cancer or melanoma with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies

New patents expected to expire in 2034

Immodulon’s IMM-101 is currently in a phase II clinical trial in combination with checkpoint inhibitor therapy in advanced melanoma

Immodulon, the immuno-oncology company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No’s. 16/112,430 and 15/104,890 related to IMM-101, the Company’s investigational treatment comprising heat-killed Mycobacterium obuense for various tumour types, including melanoma and pancreatic cancer.

The allowed claims cover methods of treating melanoma with IMM-101 in combination with anti-PD1, anti-PD-L1 or anti-CTLA4 antibodies, and methods of treating pancreatic cancer with IMM-101 in combination with anti-PD-L1 antibodies. Upon grant, both patents are expected to expire in 2034. The Company intends to conduct further clinical studies related to the allowed claim scope and advance IMM-101 into other cancers with high unmet need.

Dr Jaap Kampinga, Chief Executive Officer of Immodulon, commented:
“We are pleased to have received these Notices of Allowance which cover methods of treating both melanoma and pancreatic cancer with IMM-101 in combination with checkpoint inhibitors. Immodulon is pursuing multiple avenues for securing and enhancing our intellectual property protection for IMM-101. These new patents complement our ongoing phase II clinical trial of IMM-101 in combination with checkpoint inhibitor therapy in advanced melanoma, and support ongoing discussions with third parties as well as key studies in preparation for the treatment of pancreatic cancer.”

About Immodulon’s current advanced melanoma trial
IMM-101-015 (NCT03711188) is an ongoing open label phase 2 study that will enroll up to 26 patients with unresectable stage III or stage IV melanoma who are either treatment-naive (18 patients) or whose disease has progressed during or after treatment with PD-1 blockade (8 patients). The primary objective of the trial is to assess the safety and efficacy of the combination of IMM-101 with nivolumab. Secondary objectives include overall survival and progression-free survival at 18 months.

About Immodulon Therapeutics
Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system by several mechanisms, including via Toll-like receptors. Its mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and other standard-of care treatments, it is expected to enhance their efficacy without increasing the safety burden for the patient. For more information about Immodulon, please visit www.immodulon.com.